Spravato

SCOTTSDALE, Ariz. – October 30, 2026 -- LifeStance Health (Nasdaq: LFST) reports that 74% of its patients with treatment-resistant depression achieved a clinically meaningful reduction in symptoms after 12 weeks of esketamine (Spravato), while 61% of TMS patients improved after at least 30 sessions. The outpatient mental healthcare provider is expanding access to both specialty services across the U.S.

Esketamine analysis covers 258 patients and shows suicidal ideation falling to 2%

LifeStance tracked progress with the Patient Health Questionnaire (PHQ-9). It defines clinically meaningful improvement as a score reduction of five or more points.

Among the 258 esketamine patients, the share reporting suicidal ideation nearly every day fell from 13% before treatment to 2% afterward, an 85% reduction.